Skip to main content

Table 5 Number of studies reporting parameters which could influence the cost-effectiveness results

From: Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

Therapeutic area Epidemiological and disease progression parameters Clinical effectiveness data Resource use and cost parameters
probability of ADRs allele frequency PPV/NPV mortality rate of ADRs efficacy of genetic testing efficacy of drugs treatment cost of testing costs of alternative drugs cost of hospitalization
Cardiovascular disease (n = 24)
CYP2C19 -Clopidogrel [30, 33, 34]    [31]   [35]   [36] [38]
CYP2C9 and VKORC1 -Warfarin [17, 21, 25]     [16, 22, 26, 28, 29]   [23, 24] [19]  
 pharmacogenetic testing-Statin       [39]    
Gout (n = 8)
HLA-B*58:01 -Allopurinol [43, 44, 46] [45]     [40] [42] [44] [40, 47]
HIV infection (n = 8)
HLA-B*57:01 -Abacavir   [50]   [49]    [51, 52] [53, 54]  
CYP2B6 -Efavirenz        [55]   
Autoimmune disease (n = 8)
TPMT - Azathioprine   [57] [62]   [63]   [56, 58] [60]  
Epilepsy/neuropathic pain (n = 6)
HLA-B*15:02 or HLA-A*31:01 -Carbamazepine    [67, 68]    [64, 69]   [65, 67]  
Cancer (n = 3)
UGT1A1 -Irinotecan      [71] [72]    
DPYD -Fluoropyrimidine [70]         
Major depressive disorder (n = 1)
CYP2D6 -Nortriptyline      [73] [73]    
Hormone replacement therapy (n = 1)
 Factor V Leiden-Estrogen combined in oral contraceptives          
  1. ADRs: Adverse Drug Reactions, PPV: Positive Predictive Value, NPV: Negative Predictive Value